Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

Show full item record



Permalink

http://hdl.handle.net/10138/195929

Citation

Malani , D , Murumagi , A , Yadav , B , Kontro , M , Eldfors , S , Kumar , A , Karjalainen , R , Majumder , M M , Ojamies , P , Pemovska , T , Wennerberg , K , Heckman , C , Porkka , K , Wolf , M , Aittokallio , T & Kallioniemi , O 2017 , ' Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML ' , Leukemia , vol. 31 , no. 5 , pp. 1187-1195 . https://doi.org/10.1038/leu.2016.314

Title: Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
Author: Malani, D.; Murumagi, A.; Yadav, B.; Kontro, M.; Eldfors, S.; Kumar, A.; Karjalainen, R.; Majumder, M. M.; Ojamies, P.; Pemovska, T.; Wennerberg, K.; Heckman, C.; Porkka, K.; Wolf, M.; Aittokallio, T.; Kallioniemi, O.
Contributor: University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Medicum
University of Helsinki, Clinicum
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Clinicum
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
Date: 2017-05
Language: eng
Number of pages: 9
Belongs to series: Leukemia
ISSN: 0887-6924
URI: http://hdl.handle.net/10138/195929
Abstract: We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (AML) by generating eight resistant variants from MOLM-13 and SHI-1 AML cell lines by long-term drug treatment. These cells were compared with 66 ex vivo chemorefractory samples from cytarabine-treated AML patients. The models and patient cells were subjected to genomic and transcriptomic profiling and high-throughput testing with 250 emerging and clinical oncology compounds. Genomic profiling uncovered deletion of the deoxycytidine kinase (DCK) gene in both MOLM-13- and SHI-1-derived cytarabine-resistant variants and in an AML patient sample. Cytarabine-resistant SHI-1 variants and a subset of chemorefractory AML patient samples showed increased sensitivity to glucocorticoids that are often used in treatment of lymphoid leukemia but not AML. Paired samples taken from AML patients before treatment and at relapse also showed acquisition of glucocorticoid sensitivity. Enhanced glucocorticoid sensitivity was only seen in AML patient samples that were negative for the FLT3 mutation (P = 0.0006). Our study shows that development of cytarabine resistance is associated with increased sensitivity to glucocorticoids in a subset of AML, suggesting a new therapeutic strategy that should be explored in a clinical trial of chemorefractory AML patients carrying wild-type FLT3.
Subject: ACUTE MYELOID-LEUKEMIA
ACUTE LYMPHOBLASTIC-LEUKEMIA
DRUG-RESISTANCE
CELL-LINES
IN-VITRO
DEOXYCYTIDINE KINASE
ONCOLOGY-GROUP
ARA-C
EXPRESSION
DEXAMETHASONE
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
leu2016314a.pdf 1.043Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record